SOLO-1: OS With 7-Yr Follow-up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation Who Received Maintenance Olaparib

September 9-13, 2022; Paris, France
The 7-year follow-up from SOLO-1 shows continued survival benefit for patients with newly diagnosed advanced ovarian cancer who were treated with maintenance olaparib for up to 2 years vs placebo.
Format: Microsoft PowerPoint (.ppt)
File Size: 225 KB
Released: September 15, 2022

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Bristol-Myers Squibb
Exelixis, Inc.
Gilead Sciences, Inc.
Merck Sharp & Dohme Corp.

Related Content

Experts provide their thoughts on key data in breast, gynecologic, renal cell, urothelial, lung, hepatobiliary, and skin cancers presented at the 2022 ESMO Congress, from Clinical Care Options (CCO)

Nicoletta Colombo, MD Robert Motzer, MD person default Sapna P. Patel, MD David Planchard, MD, PhD Elizabeth R. Plimack, MD, MS Rachna Shroff, MD Sara Tolaney, MD, MPH Physicians: maximum of 1.25 AMA PRA Category 1 Credits Released: November 14, 2022 Expired: November 13, 2023

Downloadable slideset updated with highlights of key gynecologic oncology studies presented at conferences throughout 2022, from Clinical Care Options (CCO)

Susana Banerjee, MBBS, MA, PhD, FRCP Jubilee Brown, MD person default Elisabeth Diver, MD person default Alexandra Leary, MD, PhD Domenica Lorusso, MD, PhD David Scott Miller, MD, FACOG, FACS person default Mansoor Raza Mirza, MD Prof Isabelle Ray-Coquard, MD, PhD Angeles Alvarez Secord, MD, MHSc Ignace Vergote, MD, PhD Released: November 10, 2022

Expert commentary on new clinical trial data in cervical cancer and ovarian cancer, from Clinical Care Options (CCO)

Susana Banerjee, MBBS, MA, PhD, FRCP person default Mansoor Raza Mirza, MD Released: November 3, 2022

Expert commentary on PARP inhibitors in ovarian cancer, from Clinical Care Options (CCO)

person default Alexandra Leary, MD, PhD Domenica Lorusso, MD, PhD Released: October 19, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings